Henriksen, P. A. et al. (2022) Rationale and design of the Cardiac CARE trial: A randomized trial of troponin-guided neurohormonal blockade for the prevention of anthracycline cardiotoxicity. Circulation: Heart Failure, 15(7), e009445. (doi: 10.1161/CIRCHEARTFAILURE.121.009445) (PMID:35766037)
![[img]](https://eprints.gla.ac.uk/style/images/fileicons/text.png) |
Text
273813.pdf - Accepted Version 736kB |
Abstract
Background: Anthracyclines are effective cytotoxic drugs used in the treatment of breast cancer and lymphoma but are associated with myocardial injury, left ventricular dysfunction, and heart failure. Anthracycline-induced cardiotoxicity is highly variable in severity and without a proven therapeutic intervention. β-Adrenergic receptor blockers and renin-angiotensin-system inhibitor therapies have been associated with modest cardioprotective effects in unselected patients. Methods: The Cardiac CARE trial is a multicentre prospective randomized open-label blinded end point trial of combination β-adrenergic receptor blocker and renin-angiotensin-system inhibitor therapy in patients with breast cancer and non-Hodgkin lymphoma receiving anthracycline chemotherapy that is associated with myocardial injury. Patients at higher risk of cardiotoxicity with plasma high-sensitivity cTnI (cardiac troponin I) concentrations in the upper tertile at the end of chemotherapy are randomized to standard of care plus combination candesartan and carvedilol therapy or standard of care alone. All patients undergo cardiac magnetic resonance imaging before and 6 months after anthracycline treatment. The primary end point is the change in left ventricular ejection fraction at 6 months after chemotherapy. In low-risk nonrandomized patients, left ventricular ejection fraction before and 6 months after anthracycline will be compared with define the specificity of the high-sensitivity cTnI assay for identifying low-risk participants who do not develop left ventricular systolic dysfunction. Discussion: Cardiac CARE will examine whether cardiac biomarker monitoring identifies patients at risk of left ventricular dysfunction following anthracycline chemotherapy and whether troponin-guided treatment with combination candesartan and carvedilol therapy prevents the development of left ventricular dysfunction in these high-risk patients.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | Lang, Professor Ninian and McKay, Dr Pamela and MacPherson, Professor Iain |
| Authors: | Henriksen, P. A., Hall, P., Oikonomidou, O., MacPherson, I. R., Maclean, M., Lewis, S., McVicars, H., Broom, A., Scott, F., McKay, P., Borley, A., Rowntree, C., Lord, S., Collins, G., Radford, J., Guppy, A., Payne, J. R., Newby, D. E., Mills, N. L., and Lang, N. N. |
| College/School: | College of Medical Veterinary and Life Sciences > School of Cancer Sciences College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health |
| Journal Name: | Circulation: Heart Failure |
| Publisher: | American Heart Association |
| ISSN: | 1941-3289 |
| ISSN (Online): | 1941-3297 |
| Published Online: | 29 June 2022 |
| Copyright Holders: | Copyright © 2022 American Heart Association, Inc. |
| First Published: | First published in Circulation: Heart Failure 15(7): e009445 |
| Publisher Policy: | Reproduced in accordance with the publisher copyright policy |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information